

PROFESSIONAL INFORMATION



38007 P3

USN ZMA+

(capsules)

COMPLEMENTARY MEDICINE: HEALTH SUPPLEMENT

This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.

SCHEDULING STATUS: S0

1. NAME OF THE MEDICINE

USN ZMA+ capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ACTIVE INGREDIENTS:

	Per Capsule	Per Dose	*%NRV
ZMA [®]	305,6 mg	1 222,5 mg	
providing Magnesium (from Magnesium Citrate and Magnesium Oxide)	62,4 mg	250 mg	60 %
Zinc (from Zinc Mono-L-Methionine)	4,2 mg	17 mg	155 %
Vitamin B ₆ (from Pyridoxine HCl)	1,5 mg	6 mg	353 %
Beta-alanine	12,5 mg	50 mg	
Ascorbic acid (Vitamin C)	10 mg	40 mg	40 %
Vitamin E acetate (50 %)	5 mg	20 mg	
providing Vitamin E	2,5 mg	10 mg	67 %

*%Nutrient Reference Values (NRVs) for individuals 4 years and older (2010).

Sugar free.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Capsules.

Size 0, white and light blue, hard gelatine capsules containing a white powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

USN ZMA+ is indicated as an anabolic recovery aid for optimal athletic performance. USN ZMA+ may improve physical performance and exercise capacity and help to delay muscle fatigue during physical activity.

4.2 Posology and method of administration

Adults:

- MEN: Take 2 – 4 capsules daily, preferably on an empty stomach 30 – 60 minutes before bedtime.
- WOMEN: Take 2 – 3 capsules daily, preferably on an empty stomach 30 – 60 minutes before bedtime.
- For best results, avoid taking with dairy or other calcium-containing foods or supplements.
- Do not exceed the recommended daily dosage.

Children:

Not suitable for children under the age of 18 years.

4.3 Contraindications

Hypersensitivity to any of the active ingredients or to any of the excipients listed in section 2 or 6.1.

4.4 Special warnings and precautions for use

Bleeding disorders:

USN ZMA+ may have antiplatelet effects and may increase the risk of bruising and bleeding when used in patients with bleeding disorders. Patients should be advised to discontinue USN ZMA+ at least 2 weeks prior to surgical procedures (see section 4.5).

Renal disease:

USN ZMA+ should be used with caution in patients with existing renal disease.

Flushing and/or tingling sensation:

USN ZMA+ may cause a flushing, tingling and/or prickling sensation of the skin, in which case, the dose should be reduced.

4.5 Interaction with other medicinal products and other forms of interaction

Anticoagulant/antiplatelet medicines:

USN ZMA+ may enhance the effects of anticoagulant/antiplatelet medicines or herbal supplements. Concomitant use may increase the risk of bruising and bleeding (see section 4.4).

Antibiotic medicines:

USN ZMA+ may decrease the absorption of antibiotics. Doses should be separated by at least 2 hours prior, or 4 to 6 hours after taking USN ZMA+.

4.6 Fertility, pregnancy and lactation

Safety in pregnancy and lactation has not been established.

USN ZMA+ should not be taken during pregnancy or lactation.

4.7 Effects on ability to drive and use machines

USN ZMA+ may cause side effects, such as somnolence, which can affect the ability to drive a vehicle and use machines (see section 4.8).

Caution is advised before driving a vehicle or operating machinery until the effects of USN ZMA+ are known.

4.8 Undesirable effects

USN ZMA+ is generally well tolerated.

Immune system disorders:

Frequency unknown: hypersensitivity and/or allergic reactions.

Psychiatric disorders:

Frequency unknown: insomnia, somnolence.

Nervous system disorders:

Frequency unknown: paraesthesia, headache.

Vascular disorders:

Frequency unknown: flushing.

Gastrointestinal disorders:

Frequency unknown: gastrointestinal irritation, abdominal pain or cramps, nausea, vomiting, dyspepsia, diarrhoea.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of USN ZMA+ is important. It allows continued monitoring of the benefit/risk balance of USN ZMA+. Healthcare providers are asked to report any suspected adverse reactions to the South African Health Products Regulatory Authority (SAHPRA) via the 6.04 Adverse Drug Reaction Reporting Form, found online under SAHPRA's publications: <https://www.sahpra.org.za/Publications/Index/8>.

4.9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity (see section 4.8).

In the event of overdose, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Category and class:

D 34.12 Multiple Substance Formulation.

USN ZMA+ contains vitamins, minerals and beta-alanine to improve physical/athletic performance and exercise capacity and help to delay muscle fatigue during physical activity.

5.2 Pharmacokinetic properties

Magnesium requires both parathyroid hormone and vitamin D for absorption. Magnesium is absorbed throughout the gastrointestinal tract, is distributed in the skeleton and soft tissue, and excreted primarily via the kidneys.

Zinc is absorbed in the small intestines, distributed in the body in skeletal muscle and bone and mainly excreted through the faeces.

Pyridoxine (Vitamin B₆) is passively absorbed from the upper gastrointestinal tract, converted in the liver to coenzyme pyridoxal phosphate and excreted in the urine.

After supplementation with beta-alanine, muscle carnosine levels are increased. When beta-alanine is taken orally, the plasma half-life is about 25 minutes. Small amounts are excreted unchanged in the urine.

Ascorbic acid (Vitamin C) is readily absorbed from the gastrointestinal tract and is widely distributed in the body. The main route of elimination is through urine.

Vitamin E is mostly absorbed in the small intestines by passive diffusion and is excreted mainly unchanged via the faeces.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Gelatine capsules (bovine)

Magnesium stearate

Potato starch

Silicon dioxide.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months.

Store at or below 25 °C.

6.4 Special precautions for storage

Store in a dry place.

6.5 Nature and contents of container

120 capsules are packed in a cobalt blue PET container with a white screw-on cap and induction seal.

6.6 Special precautions for disposal

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

USN (Pty) Ltd

Unit 4, Louwlandia Logistics Park

cnr Nellmapius Drive & Olieverhoutbosch Road

Centurion, 1683

Pretoria

8. REGISTRATION NUMBER

Will be allocated by SAHPRA upon registration.


9. DATE OF FIRST AUTHORISATION

Will be allocated by SAHPRA upon registration.

10. DATE OF REVISION OF THE TEXT

This leaflet was last revised in June 2021.

ZMA001/PI-PII/A

JOB: SACS_ZMA Plus_120s	SIZE: 300mm x 295mm
STOCK: Foil Substrate: <input type="checkbox"/> Clear Substrate: <input type="checkbox"/> White Substrate: <input type="checkbox"/> Paper: <input checked="" type="checkbox"/> Other: <input type="checkbox"/>	
COLOURS:  K	FINISHING: <input type="checkbox"/> Foil / Holographic Foil <input type="checkbox"/> Matte <input type="checkbox"/> Gloss <input type="checkbox"/> Spot UV <input type="checkbox"/> Doming <input type="checkbox"/> Embossing
PLEASE CHECK CAREFULLY	Although we endeavour to proof accurately, we cannot accept responsibility for errors once proofs are signed and accepted by our clients.

